☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BeiGene
BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma
October 22, 2024
BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024
June 14, 2024
The US FDA Grants Approval to BeiGene’s Tevimbra to Treat Advanced or Metastatic Esophageal Squamous Cell Carcinoma
March 15, 2024
BeiGene’s Brukinsa Receives the US FDA’s Accelerated Approval for the Treatment of Follicular Lymphoma (FL)
March 8, 2024
BeiGene Reports Results from a Comparative Analysis of Brukinsa vs Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia...
March 1, 2024
BeiGene’s Tevimbra (tislelizumab) Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
February 27, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.